Guideline:
Bibliographic Source(s)
- ASGE Standards of Practice Committee Ikenberry SO Harrison ME Lichtenstein D Dominitz JA Anderson MA Jagannath SB Banerjee S Cash BD Fanelli RD Gan SI Shen B Van Guilder T Lee KK Baron TH. The role of endoscopy in dyspepsia. Gastrointest EndoscĀ 2007 Dec;66(6):1071-5. [40 references] PubMed
Guideline Status
This is the current release of the guideline.
This guideline updates a previous version: Eisen GM Dominitz JA Faigel DO Goldstein JA Kalloo AN Petersen BT Raddawi HM Ryan ME Vargo JJ 3rd Young HS Fanelli RD Hyman NH Wheeler-Harbaugh J. The role of endoscopy in dyspepsia. Gastrointest Endosc 2001 Dec;54(6):815-7. [24 references] PubMed
Guideline Category
Diagnosis
Evaluation
Management
Risk Assessment
Intended Users
Physicians
Guideline Objective(s)
To define the role of upper endoscopy in the diagnostic evaluation and management of patients with dyspepsia
Target Population
Patients with dyspepsia
Note: Patients with heartburn are excluded from this guideline.
Interventions and Practices Considered
- "Test-and-treat" approach including noninvasive testing for Helicobacter pylori (H pylori) such as serology urea breath testing (UBT) and stool antigen and subsequent treatment of H pylori
- Endoscopy
- Acid suppressive agents (proton pump inhibitors)
Major Outcomes Considered
- Sensitivity specificity and negative and positive predictive values of diagnostic tests
- Signs and symptoms
Methods Used to Collect/Select Evidence
Hand-searches of Published Literature (Primary Sources)
Searches of Electronic Databases
Description of Methods used to Collect/Select the Evidence
In preparing this guideline a search of the medical literature was performed by using PubMed supplemented by accessing the "related articles" feature of PubMed. Additional references were obtained from the bibliographies of the identified articles and from recommendations of expert consultants. When little or no data exist from well-designed prospective trials emphasis is given to results from large series and reports from recognized experts.
Number of Source Documents
Not stated
Methods Used to Assess the Quality and Strength of the Evidence
Expert Consensus
Rating Scheme for the Strength of the Evidence
Not applicable
Methods Used to Analyze the Evidence
Review of Published Meta-Analyses
Systematic Review
Description of the Methods Used to Analyze the Evidence
Not stated
Methods Used to Formulate the Recommendations
Expert Consensus
Description of Methods Used to Formulate the Recommendations
Guidelines for appropriate utilization of endoscopy are based on a critical review of the available data and expert consensus at the time the guidelines are drafted.
Rating Scheme for the Strength of the Recommendations
Grades of Recommendation*
| Grade of Recommendation | Clarity of Benefit | Methodologic Strength/ Supporting Evidence | Implications |
|---|---|---|---|
| 1A | Clear | Randomized trials without important limitations | Strong recommendation; can be applied to most clinical settings |
| 1B | Clear | Randomized trials with important limitations (inconsistent results nonfatal methodologic flaws) | Strong recommendation; likely to apply to most practice settings |
| 1C+ | Clear | Overwhelming evidence from observational studies | Strong recommendation; can apply to most practice settings in most situations |
| 1C | Clear | Observational studies | Intermediate-strength recommendation; may change when stronger evidence is available |
| 2A | Unclear | Randomized trials without important limitations | Intermediate-strength recommendation; best action may differ depending on circumstances or patients' or societal values |
| 2B | Unclear | Randomized trials with important limitations (inconsistent results nonfatal methodologic flaws) | Weak recommendation; alternative approaches may be better under some circumstances |
| 2C | Unclear | Observational studies | Very weak recommendation; alternative approaches likely to be better under some circumstances |
| 3 | Unclear | Expert opinion only | Weak recommendation; likely to change as data become available |
*Adapted from Guyatt G Sinclair J Cook D Jaeschke R Schunemann H Pauker S. Moving from evidence to action: grading recommendations—a qualitative approach. In: Guyatt G Rennie D eds. Users' guides to the medical literature. Chicago: AMA Press; 2002. p. 599-608.
Cost Analysis
Published cost analyses were reviewed.
The test-and-treat approach is more cost effective than the initial endoscopy approach. Results from a meta-analysis of 5 randomized studies of test-and-treat versus an initial endoscopy showed a negligible improvement of symptoms in the endoscopy group but a savings of $389 per patient in the test-and-treat group. Results from a large randomized study that compared test-and-treat with initial endoscopy found no significant difference in dyspeptic symptoms at 1 year but with a 60% reduction in endoscopy utilization in the test-and-treat group.
A decision analysis of one study showed that cost-effectiveness of the test-and-treat approach versus empiric acid suppression depends on the prevalence of Helicobacter pylori (H pylori). If the incidence of H pylori is <20% then empiric acid-suppression therapy is more cost>
Method of Guideline Validation
Internal Peer Review
Description of Method of Guideline Validation
This document was reviewed and approved by the Governing Board of the American Society for Gastrointestinal Endoscopy.
Major Recommendations
Recommendations were graded on the strength of the supporting evidence (Grades 1A--3). Definitions of the recommendation grades are presented at the end of the "Major Recommendations" field.
Summary
- Patients with dyspepsia who are older than 50 years of age and/or those with alarm features should undergo endoscopic evaluation. (1C)
- Patients with dyspepsia who are younger than 50 years of age and without alarm features may undergo an initial test-and-treat approach for Helicobacter pylori (H pylori). (1B)
- Patients who are younger than 50 years of age and are H pylori negative can be offered an initial endoscopy or a short trial of proton-pump inhibitors (PPI) acid suppression. (2B)
- Patients with dyspepsia who do not respond to empiric PPI therapy or have recurrent symptoms after an adequate trial should undergo endoscopy. (3)
Definitions:
Grades of Recommendation*
| Grade of Recommendation | Clarity of Benefit | Methodologic Strength/ Supporting Evidence | Implications |
|---|---|---|---|
| 1A | Clear | Randomized trials without important limitations | Strong recommendation; can be applied to most clinical settings |
| 1B | Clear | Randomized trials with important limitations (inconsistent results nonfatal methodologic flaws) | Strong recommendation; likely to apply to most practice settings |
| 1C+ | Clear | Overwhelming evidence from observational studies | Strong recommendation; can apply to most practice settings in most situations |
| 1C | Clear | Observational studies | Intermediate-strength recommendation; may change when stronger evidence is available |
| 2A | Unclear | Randomized trials without important limitations | Intermediate-strength recommendation; best action may differ depending on circumstances or patients' or societal values |
| 2B | Unclear | Randomized trials with important limitations (inconsistent results nonfatal methodologic flaws) | Weak recommendation; alternative approaches may be better under some circumstances |
| 2C | Unclear | Observational studies | Very weak recommendation; alternative approaches likely to be better under some circumstances |
| 3 | Unclear | Expert opinion only | Weak recommendation; likely to change as data become available |
*Adapted from Guyatt G Sinclair J Cook D Jaeschke R Schunemann H Pauker S. Moving from evidence to action: grading recommendations—a qualitative approach. In: Guyatt G Rennie D eds. Users' guides to the medical literature. Chicago: AMA Press; 2002. p. 599-608.
Clinical Algorithm(s)
A clinical algorithm is provided in the original guideline document for evaluation of dyspepsia.
Type of Evidence supporting the Recommendations
The type of supporting evidence is identified for each recommendation (see "Major Recommendations").
Potential Benefits
Appropriate diagnostic evaluation and management of dyspepsia
Potential Harms
Drawbacks to the test-and-treat approach include the risk of Clostridium difficile-associated colitis and induction of antibiotic resistance.
Qualifying Statements
- Further controlled clinical studies may be needed to clarify aspects of this guideline. This guideline may be revised as necessary to account for changes in technology new data or other aspects of clinical practice.
- This guideline is intended to be an educational device to provide information that may assist endoscopists in providing care to patients. This guideline is not a rule and should not be construed as establishing a legal standard of care or as encouraging advocating requiring or discouraging any particular treatment. Clinical decisions in any particular case involve complex analysis of the patient's condition and available courses of action. Therefore clinical considerations may lead an endoscopist to take a course of action that varies from these guidelines.
Description of Implementation Strategy
An implementation strategy was not provided.
Implementation Tools
Clinical Algorithm
For information about availability see the "Availability of Companion Documents" and "Patient Resources" fields below.
IOM Care Need
Getting Better
Living with Illness
IOM Domain
Effectiveness
Bibliographic Source(s)
- ASGE Standards of Practice Committee Ikenberry SO Harrison ME Lichtenstein D Dominitz JA Anderson MA Jagannath SB Banerjee S Cash BD Fanelli RD Gan SI Shen B Van Guilder T Lee KK Baron TH. The role of endoscopy in dyspepsia. Gastrointest EndoscĀ 2007 Dec;66(6):1071-5. [40 references] PubMed
Adaptation
Not applicable: The guideline was not adapted from another source.
Source(s) of Funding
American Society for Gastrointestinal Endoscopy
Guideline Committee
Standards of Practice Committee
Composition of Group that Authored the Guideline
Committee Members: Steven O. Ikenberry MD; M. Edwyn Harrison MD; David Lichtenstein MD; Jason A. Dominitz MD MHS; Michelle A. Anderson MD; Sanjay B. Jagannath MD; Subhas Banerjee MD; Brooks D. Cash MD; Robert D. Fanelli MD SAGES Representative; Seng-Ian Gan MD; Bo Shen MD; Trina Van Guilder RN SGNA Representative; Kenneth K. Lee MD NAPSGHAN Representative; Todd H. Baron MD Chair
Financial Disclosures/Conflicts of Interest
Not stated
Guideline Status
This is the current release of the guideline.
This guideline updates a previous version: Eisen GM Dominitz JA Faigel DO Goldstein JA Kalloo AN Petersen BT Raddawi HM Ryan ME Vargo JJ 3rd Young HS Fanelli RD Hyman NH Wheeler-Harbaugh J. The role of endoscopy in dyspepsia. Gastrointest Endosc 2001 Dec;54(6):815-7. [24 references] PubMed
Guideline Availability
Electronic copies: Available from the American Society for Gastrointestinal Endoscopy Web site.
Print copies: Available from the American Society for Gastrointestinal Endoscopy 1520 Kensington Road Suite 202 Oak Brook IL 60523
Availability of Companion Documents
None available
Patient Resources
None available
NGC STATUS
This NGC summary was completed by ECRI on March 23 2005. The information was verified by the guideline developer on March 31 2005. This NGC summary was updated by ECRI Institute on March 4 2008.
COPYRIGHT STATEMENT
This NGC summary is based on the original guideline which is subject to the guideline developer's copyright restrictions.
NGC Disclaimer
The National Guideline Clearinghouse™ (NGC) does not develop produce approve or endorse the guidelines represented on this site.
All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies relevant professional associations public or private organizations other government agencies health care organizations or plans and similar entities.
Guidelines represented on the NGC Web site are submitted by guideline developers and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .
NGC AHRQ and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC AHRQ or its contractor ECRI Institute and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.
Readers with questions regarding guideline content are directed to contact the guideline developer.
Tools
No Quick Reference tools have been developed.
Details
FDA Warning
- Category:
- Family Practice, Gastroenterology, Internal Medicine
- Conditions:
- DyspepsiaNote: The Rome III Committee defined dyspepsia as one or more of the following three symptoms:Postprandial fullnessEarly satietyEpigastric pain or burning
- Published:
- 2001 Dec (revised 2007 Jan)
- Endorsed by:
- American Society for Gastrointestinal Endoscopy

